Business Description
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Business History
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -5.86
Total Equity: $10.42M
Shares: 20,730,870
Total Debt: $525,000
Cash: $11.98M
EBITDA: -$12.16M
Total Debt: $525,000
Cash: $11.98M
Revenue: $1.23M
Shares: 20,730,870
Revenue: $1.23M
Revenue: $1.23M
Revenue: $1.23M
Total Equity: $10.42M
Tax Rate: 0.0%
Equity: $10.42M
Total Debt: $525,000
Cash: $11.98M
Current Liabilities: $3.74M
Long-Term Debt: $0.00
Total Debt: $525,000
Total Equity: $10.42M
Shares: 20,730,870
Shares: 20,730,870
CapEx: $0.00
Shares: 20,730,870
Stock Price: $4.92
Net Income: -$12.15M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 2, 2026 5:13pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $135,000 | $1.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $53,000 |
| Gross Profit | $0 | $0 | $0 | $135,000 | $1.2M |
| Operating Expenses | $4.4M | $11.6M | $14.2M | $18.0M | $13.4M |
| Operating Income | -$4.4M | -$11.6M | -$14.2M | -$17.8M | -$12.2M |
| Net Income | -$4.6M | -$12.2M | -$26.2M | -$24.8M | -$12.2M |
| EBITDA | -$4.4M | -$11.6M | -$11.1M | -$24.6M | -$12.2M |
| EPS | $-88.10 | $-233.80 | $-302.62 | $-66.30 | $-5.86 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 2, 2026 5:13pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $510,000 | $47,000 | $176,000 | $1.8M | $12.0M |
| Total Current Assets | $601,000 | $1.5M | $2.3M | $3.8M | $13.6M |
| Total Assets | $603,000 | $3.0M | $3.5M | $4.7M | $14.2M |
| Current Liabilities | $3.1M | $16.1M | $13.0M | $6.8M | $3.7M |
| Long-Term Debt | $244,000 | $7.7M | $4.3M | $0 | $0 |
| Total Liabilities | $3.4M | $23.8M | $17.4M | $6.8M | $3.7M |
| Total Equity | -$2.8M | -$20.8M | -$13.9M | -$2.2M | $10.4M |
| Retained Earnings | -$76.3M | -$88.5M | -$114.7M | -$139.6M | -$151.7M |
Cash Flow (Annual)
Last updated: Jul 2, 2026 5:13pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$5.1M | -$7.8M | -$10.3M | -$16.0M | -$13.6M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5.1M | -$7.8M | -$10.3M | -$16.0M | -$13.6M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $471,612 | $-463,000 | $129,000 | $1.6M | $10.2M |
Analyst Estimates (Annual)
Last updated: Jul 2, 2026 5:13pm (2h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$1.0M $1.0M – $1.0M
|
$2.0M $1.9M – $2.0M
|
$2.9M $2.9M – $3.0M
|
$16.0M $15.8M – $16.2M
|
| EBITDA |
$205,799 $203,405 – $208,193
|
$390,799 $386,253 – $395,346
|
$586,199 $579,380 – $593,019
|
$3.2M $3.2M – $3.2M
|
| Net Income |
-$132.7M -$134.7M – -$130.7M
|
-$75.5M -$76.6M – -$74.3M
|
-$48.4M -$49.1M – -$47.7M
|
-$15.8M -$16.0M – -$15.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 2, 2026 5:13pm (2h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | +814.1% |
| Gross Profit Growth | — | — | — | +774.8% |
| Operating Income Growth | -160.9% | -22.4% | -25.6% | +31.8% |
| Net Income Growth | -165.2% | -115.2% | +5.3% | +51.1% |
| EBITDA Growth | -163.6% | +3.6% | -120.7% | +50.5% |
Insider Trading (Recent)
Last updated: Jul 2, 2026 5:13pm (2h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Schlorff Eric | A-Award | 10,288.00 | $0.00 | $0 |
| 2026-07-01 | Baird Jennifer A | A-Award | 4,000.00 | $0.00 | $0 |
| 2026-02-06 | Van Heel Kenneth | A-Award | 3,000.00 | $0.00 | $0 |
| 2026-02-06 | Neuman John | A-Award | 3,000.00 | $0.00 | $0 |
| 2026-02-06 | Vincent Bernadette N | A-Award | 3,000.00 | $0.00 | $0 |
| 2026-02-06 | Baird Jennifer A | A-Award | 3,000.00 | $0.00 | $0 |
| 2026-02-06 | Towne Bradford K | A-Award | 7,500.00 | $0.00 | $0 |
| 2026-02-06 | Chung Kevin | A-Award | 15,000.00 | $0.00 | $0 |
| 2026-02-06 | Schlorff Eric | A-Award | 30,000.00 | $0.00 | $0 |
| 2025-12-19 | Baird Jennifer A | P-Purchase | 4,200.00 | $0.24 | $987 |
| 2025-12-09 | Messinger Michael | P-Purchase | 14,500.00 | $0.35 | $5,098 |
| 2025-11-14 | Messinger Michael | 0.00 | $0.00 | $0 | |
| 2025-08-26 | Towne Bradford K | 0.00 | $0.00 | $0 | |
| 2025-08-27 | Van Heel Kenneth | P-Purchase | 10,000.00 | $0.86 | $8,565 |
| 2025-08-26 | Van Heel Kenneth | P-Purchase | 25,000.00 | $0.89 | $22,248 |
| 2025-08-22 | Chung Kevin | P-Purchase | 10,000.00 | $0.80 | $8,000 |
| 2025-07-10 | Baird Jennifer A | A-Award | 4,000.00 | $0.00 | $0 |
| 2025-07-10 | Neuman John | A-Award | 4,000.00 | $0.00 | $0 |
| 2025-06-04 | Neuman John | M-Exempt | 2,667.00 | $0.00 | $0 |
| 2025-06-04 | Neuman John | M-Exempt | 2,667.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).